Sansure Biotech Inc. (SHA:688289)

Market Cap	11.44B
Revenue (ttm)	1.58B
Net Income (ttm)	269.74M
Shares Out	574.18M
EPS (ttm)	0.46
PE Ratio	43.40
Forward PE	30.20
Dividend	0.40 (1.99%)
Ex-Dividend Date	n/a

Volume	3,984,081
Average Volume	4,712,159
Open	20.04
Previous Close	20.07
Day's Range	19.79 - 20.18
52-Week Range	16.44 - 26.36
Beta	0.67
RSI	46.66
Earnings Date	Apr 29, 2025

About Sansure Biotech

Sansure Biotech Inc. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments in China. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,006
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2024, Sansure Biotech's revenue was 1.50 billion, an increase of 48.60% compared to the previous year's 1.01 billion. Earnings were 259.03 million, a decrease of -28.78%.